Sign Out
Effect of Other Drugs on TREZILENT: CYP3A4 Inducer: Coadministration of TREZILENT with a strong CYP3A4 inducer decreases alpelisib concentration [see Pharmacology: Pharmacokinetics under Actions], which may reduce alpelisib efficacy. Avoid concomitant use of strong CYP3A4 inducers and consider an alternative concomitant drug with no or minimal potential to induce CYP3A4.
Breast Cancer Resistance Protein Inhibitors: Coadministration of TREZILENT with a breast cancer resistance protein (BCRP) inhibitor may increase alpelisib concentration [see Pharmacology: Pharmacokinetics under Actions], which may increase the risk of toxicities. Avoid the use of BCRP inhibitors in patients treated with TREZILENT. If unable to use alternative drugs, when TREZILENT is used in combination with BCRP inhibitors, closely monitor for increased adverse reactions.
